reMYND

Foundation date

07/02/2002

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).

Upcoming events

Latest news

  • Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

    1 day ago

  • Celyad announces management change

    Friday December 1st 2023

  • Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

    Thursday November 30th 2023

Jobs by reMYND